Effective Blood Concentration of Micafungin for Pulmonary Aspergillosis

Pulmonary Aspergillosis in Ostrich

Intravenous micafungin versus voriconazole for chronic pulmonary aspergillosis: a multicenter trial in Japan.

Chronic pulmonary aspergillosis (CPA) is slowly progressive inflammatory pulmonary syndrome due to Aspergillus spp. The evidence regarding CPA treatment is limited. We conducted a randomized, multicenter, open-label trial comparing intravenous micafungin (MCFG) of 150-300 mg once daily with intravenous voriconazole (VRCZ) of 6 mg/kg twice on Day 1 followed by 4 mg/kg twice daily for the treatme...

Combination therapy with micafungin and amphotericin B for invasive pulmonary aspergillosis in an immunocompromised mouse model.

OBJECTIVES Antifungal monotherapy with polyenes, azoles or echinocandins is not always effective for invasive pulmonary aspergillosis (IPA). The main purpose of this study was to evaluate the efficacy of a combination of micafungin and amphotericin B for the primary treatment of IPA in an immunocompromised mouse model. METHODS Female ICR mice were used in all experiments. An immunosuppressive...

Micafungin in the treatment of invasive candidiasis and invasive aspergillosis

Micafungin is an echinocandin antifungal agent available for clinical use in Japan, Europe, and the United States. Through inhibition of β-1,3-glucan production, an essential component of the fungal cell wall, micafungin exhibits potent antifungal activity against key pathogenic fungi, including Candida and Aspergillus species, while contributing minimal toxicity to mammalian cells. This activi...

Antifungal prophylaxis is effective against murine invasive pulmonary aspergillosis.

Antifungal prophylaxis for patients at high risk for aspergillosis is appealing due to the high morbidity and mortality of aspergillosis despite antifungal therapy (1–3). While voriconazole is a logical option, reports of breakthrough mucormycosis are a cause for concern (5). To identify alternative prophylactic strategies, we utilized our novel, inhalational model of pulmonary Aspergillus fumi...